ATG-022 Antibody
ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human
|
CLDN18.2 |
ATG-022 Antibody potently reduces viability of CLDN18.2-overexpressing CHOK1 cells with an IC50 of 5-7 nM after conjugating with VcMMAE[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ATG-022 Antibody (3-10 mg/kg; i.v.; two doses every two weeks) induces tumor regression at 10 mg/kg in low CLDN18.2-expressing gastric cancer PDX models, while 3 mg/kg shows no antitumor activity after conjugating with VcMMAE[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunocompromised mice[2]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.v.; two doses every two weeks
-
Result:Induced 35.41% tumor growth inhibition (%TGI) at 1 mg/kg.
Induced 71.56% TGI at 3 mg/kg.
Induced tumor regression at 10 mg/kg.
-
Animal Model:Immunocompromised mice[2]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:i.v.; two doses every two weeks
-
Result:Did not inhibit tumor growth at 3 mg/kg.
Induced tumor regression at 10 mg/kg.
CLDN18.2
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)